MIGS + MEDS University Video: What can VYZULTA® do for glaucoma patients?

This video sponsored by Bausch + Lomb features the what, where, why and how of the ocular medication VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% and is part of
the video series MIGS + MEDS University. The series is a solution to help understand
the numerous medications used to treat glaucoma and ocular hypertensive patients,
and will cover the new, the old, the current, and pipeline glaucoma medications.
The intent of MIGS + MEDS University is to reduce the confusion and overwhelm
coming from the how and where to use the many glaucoma drop options.
In this video Dr. Constance Okeke, a glaucoma specialist, MIGS expert, speaker,
trainer and author, takes the viewer through an engaging, yet succinct and
informative introduction to VYZULTA. For more information on Dr. Constance
Okeke, go to www.DrConstanceOkeke.com/about.
For more information about VYZULTA, please visit: www.vyzultahcp.com/
Click here for Full Prescribing Information: www.bausch.com/Portals/69/-/m...
Stay tuned for new videos upcoming in the MIGS + MEDS University series! Be
sure to subscribe to the iGlaucoma UA-cam Channel and click the notification
bell so as not to miss the next video in the series.
Disclosure: Dr. Constance Okeke is a paid consultant of Bausch + Lomb.
INDICATION
VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
o Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
o Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
o Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
o Macular edema, including cystoid macular edema, has been reported during treatment with
prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn
posterior lens capsule, or in patients with known risk factors for macular edema
o There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
o Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
o Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye
irritation (4%), eye pain (3%), and instillation site pain (2%)
PLEASE SEE FULL PRESCRIBING INFORMATION AT www.bausch.com/Portals/69/-/m...
NEED TO SIFT THROUGH VIDEO? HERE ARE THE TIME STAMPS OF THE
IMPORTANT HIGHLIGHTS:
[0:56] What is VYZULTA?
[1:52] Why is nitric oxide important?
[2:16] Why would I choose VYZULTA?
[4:03] What about side effects?
[4:59] How do I use VYZULTA?
[6:12] Indication & Important Safety Information